# A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

> **NCT00784277** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 597 (actual)

## Conditions studied

- Joint Diseases
- Arthritis
- Osteoarthritis

## Interventions

- **DRUG:** oxycodone CR
- **DRUG:** oxycodone IR
- **DRUG:** Tapentadol ER (CG5503)
- **DRUG:** Tapentadol IR (CG5503)
- **DRUG:** Tapentadol IR (CG5503)
- **DRUG:** placebo
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00784277
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 597 (ACTUAL)
- **Last updated:** 2012-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00784277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00784277, "A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00784277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*